OSLO, Nov 10 (Reuters) - Novo Nordisk (NOVOb.CO) said on Friday it plans to invest more than 42 billion crowns ($6 billion) in the coming years as it seeks to meet booming demand for its Wegovy weight-loss treatment and other drugs. Novo Nordisk said in a statement investments include an expansion of its capacity for GLP-1 products, which include the active ingredients in Wegovy as well as the company's Ozempic diabetes treatment. "Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio," said Henrik Wulff, Novo's head of Product Supply, Quality & IT. A portion of the investment was included in a 25 billion crowns capital expenditure announced in February, Novo said. ($1 = 6.9904 Danish crowns)Reporting by Terje Solsvik, editing by Essi Lehto and Anna RingstromOur Standards: The Thomson Reuters Trust Principles.

---

Persons: Henrik Wulff, Novo's, Terje Solsvik, Essi Lehto, Anna Ringstrom Organizations: Novo Nordisk, Supply, Thomson Locations: OSLO, Denmark, Wegovy, Novo